CITY OF INDUSTRY, Calif., Jan. 17 /PRNewswire-FirstCall/ -- U.S. BioDefense, Inc. announces that they have submitted a proposal to the Department of Defense (DoD) Small Business Innovation Research (SBIR) Program.
“Terrorism relies on the element of surprise. The goal of Homeland Security is to take this advantage away by developing the intelligence and warning systems to detect terrorist movements before it manifests itself. We are committed to meeting this goal, by becoming a leading developer and commercialization company of innovative technologies, that can combat threats presented by chemical and biological agents,” said David Chin, CEO.
The DoD’s SBIR program funds early-stage R&D projects at small technology companies. The projects serve the DoD’s need for innovative technology development and have the potential for commercialization in the private and/or military markets. The program is part of a larger ($2 billion) federal SBIR program administered by ten federal agencies. For the 2005 fiscal year, the approximate funds are $1.079 billion dollars.
Under this grant program, U.S. BioDefense, Inc., has responded to one of the solicitations under the Defense Threat Reduction Agency component of the DoD. The solicitation seeks the establishment of approaches to develop a full scale testing diagnostic capability for locating, distinguishing, and quantifying a variety of Biological and Chemical Warfare agents. U.S. BioDefense, Inc., has proposed to develop a conceptual design for this system as a part of Phase I and prototype development will commence during Phase II.
The program invites companies to apply first for a six-month to nine-month phase I award of $70,000 to $100,000 to test the scientific, technical, and commercial merit and feasibility of a particular concept. If phase I proves successful, the company may be invited to apply for a two-year phase II award of $500,000 to $750,000 to further develop the concept, usually to the prototype stage. Following completion of phase II, small companies are expected to obtain funding from the private sector and/or non-SBIR government sources (in “phase III”) to develop the concept into a product for sale in private sector and/or military markets.
About U.S. BioDefense, Inc.
U.S. BioDefense is a Department of Defense central contractor that researches, develops, and commercializes leading-edge biotechnology. U.S. BioDefense, Inc. is focused on transferring, researching, and commercializing groundbreaking technology from Universities, Research Labs, Fortune 500 Companies, and Government Agencies. U.S. BioDefense subsidiary, Stem Cell Research Institute, Inc., is focused on the commercialization of breakthrough Stem Cell technologies.
U.S. BioDefense is forming a Stem Cell Center of Excellence consisting of Medical Advisors to transfer, research, develop, fund, and commercialize technology in California, and has submitted applications for several major Grants provided by the United States Department of Defense’s Chemical Biological Defense Agency and the National Institute of Health based on its Stem Cell technologies.
Safe Harbor Statement Forward-Looking Statements
Included in this release are certain “forward-looking” statements, involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the U.S. BioDefense’s financial performance. Such statements are based on management’s current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied by such statements. In addition, actual future results may differ materially from those anticipated, depending on a variety of factors, including continued maintenance of favorable license arrangements, success of market research identifying new product opportunities, successful introduction of new products, continued product innovation, the success of enhancements to the U.S. BioDefense’s brand image, sales and earnings growth, ability to attract and retain key personnel, and general economic conditions affecting consumer spending, including uncertainties relating to global political conditions, such as terrorism. Information with respect to important factors that should be considered is contained in the U.S. BioDefense’s Annual Report on Form 10-K as filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The U.S. BioDefense does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.
Contact: U.S. BioDefense David Chin, 626-961-0562 info@usbiodefense.com
U.S. BioDefense, Inc.
CONTACT: David Chin of U.S. BioDefense, +1-626-961-0562,info@usbiodefense.com
